Home LiteratureArticle Details
PMID: 16260598 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells.

Molecular and cellular biology ·Vol. 25 ·No. 22 ·2005-11-00 ·Pages 9806-19

Davies CC, Mak TW, Young LS, Eliopoulos AG

Abstract

The emerging role of CD40, a tumor necrosis factor (TNF) receptor family member, in immune regulation, disease pathogenesis, and cancer therapy necessitates the analysis of CD40 signal transduction in a wide range of tissue types. In this study we present evidence that the CD40-interacting proteins TRAF2 and TRAF6 play an important physiological role in CD40 signaling in nonhemopoietic cells. Using mutational analysis of the CD40 cytoplasmic tail, we demonstrate that the specific binding of TRAF2 to CD40 is required for efficient signaling on the NF-kappaB, Jun N-terminal protein kinase (JNK), and p38 axis. In fibroblasts lacking TRAF2 or in carcinoma cells in which TRAF2 has been depleted by RNA interference, the CD40-mediated activation of NF-kappaB and JNK is significantly reduced, and the activation of p38 and Akt is severely impaired. Interestingly, whereas the TRAF6-interacting membrane-proximal domain of CD40 has a minor role in signal transduction, studies utilizing TRAF6 knockout fibroblasts and RNA interference in epithelial cells reveal that the CD40-induced activation of NF-kappaB, JNK, p38, and Akt requires the integrity of TRAF6. Furthermore, we provide evidence that TRAF6 regulates CD40 signal transduction not only through its direct binding to CD40 but also indirectly via its association with TRAF2. These observations provide novel insight into the mechanisms of CD40 signaling and the multiple roles played by TRAF6 in signal transduction.

MeSH Terms
CD40 Antigens/biosynthesis,genetics Cell Line Cell Nucleus/metabolism Cytoplasm/metabolism DNA Mutational Analysis Enzyme-Linked Immunosorbent Assay Fibroblasts/metabolism Flow Cytometry Genes, Reporter Glutathione Transferase/metabolism HeLa Cells Humans Immunoblotting Immunoprecipitation MAP Kinase Kinase 4/metabolism Models, Biological NF-kappa B/metabolism Point Mutation Protein Binding Protein Structure, Tertiary Proto-Oncogene Proteins c-akt/metabolism RNA/chemistry RNA Interference RNA, Small Interfering/metabolism Recombinant Fusion Proteins/metabolism Signal Transduction TNF Receptor-Associated Factor 2/physiology TNF Receptor-Associated Factor 6/physiology Time Factors p38 Mitogen-Activated Protein Kinases/metabolism
Chemicals
CD40 Antigens NF-kappa B RNA, Small Interfering Recombinant Fusion Proteins TNF Receptor-Associated Factor 2 TNF Receptor-Associated Factor 6 RNA Glutathione Transferase Proto-Oncogene Proteins c-akt p38 Mitogen-Activated Protein Kinases MAP Kinase Kinase 4
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Davies Clare C
Cancer Research UK Institute for Cancer Studies, The University of Birmingham Medical School, United Kingdom.
Mak Tak W
Young Lawrence S
Eliopoulos Aristides G
References (64)
64 references, click to expand
  1. CD40-CD40 ligand.
    J Leukoc Biol. 2000 Jan;67(1):2-17 PMID: 10647992
  2. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin.
    Cancer Res. 2001 Oct 15;61(20):7556-62 PMID: 11606394
  3. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B.
    J Immunol. 1994 Nov 15;153(10):4357-66 PMID: 7525701
  4. A novel RING finger protein interacts with the cytoplasmic domain of CD40.
    J Biol Chem. 1994 Dec 2;269(48):30069-72 PMID: 7527023
  5. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.
    Cell. 1995 Jun 2;81(5):727-36 PMID: 7774014
  6. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40.
    Science. 1995 Sep 8;269(5229):1424-7 PMID: 7544915
  7. A novel function of CD40: induction of cell death in transformed cells.
    J Exp Med. 1996 Jan 1;183(1):159-67 PMID: 8551219
  8. TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation.
    Genes Dev. 1996 Apr 15;10(8):963-73 PMID: 8608943
  9. CD40 and its ligand in host defense.
    Immunity. 1996 May;4(5):415-9 PMID: 8630727
  10. CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells.
    J Immunol. 1996 Aug 15;157(4):1440-7 PMID: 8759724
  11. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling.
    Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9437-42 PMID: 8790348
  12. TRAF6 is a signal transducer for interleukin-1.
    Nature. 1996 Oct 3;383(6599):443-6 PMID: 8837778
  13. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator.
    Oncogene. 1996 Nov 21;13(10):2243-54 PMID: 8950992
  14. The functional CD40 antigen of fibroblasts may contribute to the proliferation of rheumatoid synovium.
    Clin Exp Immunol. 1996 Dec;106(3):481-90 PMID: 8973616
  15. CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation.
    J Immunol. 1997 Jan 1;158(1):144-52 PMID: 8977185
  16. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway.
    Science. 1997 Jan 10;275(5297):200-3 PMID: 8985011
  17. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors.
    Oncogene. 1997 Jun 19;14(24):2899-916 PMID: 9205097
  18. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice.
    Immunity. 1997 Nov;7(5):715-25 PMID: 9390694
  19. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts.
    J Immunol. 1998 Feb 1;160(3):1053-7 PMID: 9570516
  20. The murine buccal mucosa is an inductive site for priming class I-restricted CD8+ effector T cells in vivo.
    Clin Exp Immunol. 1998 Sep;113(3):386-93 PMID: 9737667
  21. Blockade of CD40-CD40 ligand interactions protects against radiation-induced pulmonary inflammation and fibrosis.
    Clin Immunol Immunopathol. 1998 Dec;89(3):222-30 PMID: 9837692
  22. Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40.
    Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1234-9 PMID: 9990007
  23. Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation.
    Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1421-6 PMID: 9990039
  24. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand.
    Blood. 1999 May 1;93(9):2999-3007 PMID: 10216096
  25. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.
    Genes Dev. 1999 Apr 15;13(8):1015-24 PMID: 10215628
  26. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain.
    Genes Dev. 1999 May 15;13(10):1297-308 PMID: 10346818
  27. Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and Jun N-terminal kinase activation.
    J Biol Chem. 1999 Aug 6;274(32):22414-22 PMID: 10428814
  28. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization.
    Biochemistry. 1999 Aug 3;38(31):10168-77 PMID: 10433725
  29. Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation.
    Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9803-8 PMID: 10449775
  30. TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses.
    Immunity. 1999 Sep;11(3):379-89 PMID: 10514016
  31. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells.
    Immunity. 2004 Nov;21(5):629-42 PMID: 15539150
  32. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis.
    J Immunol. 2005 Jan 1;174(1):41-50 PMID: 15611226
  33. Strength of TRAF6 signalling determines osteoclastogenesis.
    EMBO Rep. 2005 Feb;6(2):171-6 PMID: 15678156
  34. NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells.
    Cell Signal. 2005 Jun;17(6):729-38 PMID: 15722197
  35. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis.
    EMBO J. 2005 Feb 23;24(4):790-9 PMID: 15678102
  36. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor.
    J Immunol. 2000 May 15;164(10):5055-61 PMID: 10799861
  37. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily.
    Mol Cell Biol. 2000 Aug;20(15):5503-15 PMID: 10891490
  38. Molecular basis for CD40 signaling mediated by TRAF3.
    Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10395-9 PMID: 10984535
  39. Phosphatidylinositol 3-kinase and NF-kappa B/Rel are at the divergence of CD40-mediated proliferation and survival pathways.
    J Immunol. 2000 Oct 1;165(7):3860-7 PMID: 11034392
  40. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies.
    J Immunol. 2000 Nov 1;165(9):5084-96 PMID: 11046039
  41. Signal transduction by the JNK group of MAP kinases.
    Cell. 2000 Oct 13;103(2):239-52 PMID: 11057897
  42. TRAF1 is a negative regulator of TNF signaling. enhanced TNF signaling in TRAF1-deficient mice.
    Immunity. 2001 Oct;15(4):647-57 PMID: 11672546
  43. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction.
    J Cell Sci. 2002 Feb 15;115(Pt 4):679-88 PMID: 11865024
  44. The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.
    Nat Immunol. 2002 May;3(5):451-6 PMID: 11967542
  45. Signaling for survival and apoptosis in the immune system.
    Arthritis Res. 2002;4 Suppl 3:S243-52 PMID: 12110144
  46. Distinct molecular mechanism for initiating TRAF6 signalling.
    Nature. 2002 Jul 25;418(6896):443-7 PMID: 12140561
  47. The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching.
    Immunity. 2002 Sep;17(3):265-76 PMID: 12354380
  48. Prospects for CD40-directed experimental therapy of human cancer.
    Cancer Gene Ther. 2003 Jan;10(1):1-13 PMID: 12489023
  49. TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40.
    J Virol. 2003 Jan;77(2):1316-28 PMID: 12502848
  50. The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases.
    EMBO Rep. 2003 Jun;4(6):623-7 PMID: 12776182
  51. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40.
    EMBO J. 2003 Aug 1;22(15):3855-64 PMID: 12881420
  52. TRAF6 is a critical factor for dendritic cell maturation and development.
    Immunity. 2003 Sep;19(3):353-63 PMID: 14499111
  53. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling.
    J Biol Chem. 2003 Nov 14;278(46):45382-90 PMID: 12958312
  54. Tumor necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappaB activation.
    J Biol Chem. 2004 Jan 2;279(1):677-85 PMID: 14557256
  55. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells.
    J Biol Chem. 2004 Jan 9;279(2):1010-9 PMID: 14581487
  56. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes.
    J Exp Med. 2004 Mar 1;199(5):661-71 PMID: 14981114
  57. The role of the CD40 pathway in the pathogenesis and treatment of cancer.
    Curr Opin Pharmacol. 2004 Aug;4(4):360-7 PMID: 15251129
  58. Germinal center kinase is required for optimal Jun N-terminal kinase activation by Toll-like receptor agonists and is regulated by the ubiquitin proteasome system and agonist-induced, TRAF6-dependent stabilization.
    Mol Cell Biol. 2004 Oct;24(20):9165-75 PMID: 15456887
  59. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes.
    Int J Cancer. 1989 May 15;43(5):786-94 PMID: 2469656
  60. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain.
    Cell. 2000 Oct 13;103(2):351-61 PMID: 11057907
  61. Regulation of translation initiation by FRAP/mTOR.
    Genes Dev. 2001 Apr 1;15(7):807-26 PMID: 11297505
  62. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity.
    J Exp Med. 2001 Sep 3;194(5):615-28 PMID: 11535630
  63. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1.
    EMBO J. 2001 Oct 15;20(20):5678-91 PMID: 11598011
  64. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas.
    EMBO J. 1989 May;8(5):1403-10 PMID: 2475341
Article Info
Journal
Molecular and cellular biology
Abbr.
Mol Cell Biol
ISSN
0270-7306
Published
2005-11-00
Pages
9806-19
Language
English
Region
United States
NLM ID
8109087
PMCID
PMC1280261
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com